Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2021-12, Vol.21 (12), p.e985-e999
Hauptverfasser:	Abrisqueta, Pau, Loscertales, Javier, Terol, Maria José, Ramírez Payer, Ángel, Ortiz, Macarena, Pérez, Inmaculada, Cuellar-García, Carolina, Fernández de la Mata, Margarita, Rodríguez, Alicia, Lario, Ana, Delgado, Julio, Godoy, Ana, Arguiñano Pérez, José Mª, Berruezo, Mª José, Oliveira, Ana, Hernández-Rivas, José-Ángel, García Malo, Maria Dolores, Medina, Ángeles, García Martin, Paloma, Osorio, Santiago, Baltasar, Patricia, Fernández-Zarzoso, Miguel, Marco, Fernando, Vidal Manceñido, Mª Jesús, Smucler Simonovich, Alicia, López Rubio, Montserrat, Jarque, Isidro, Suarez, Alexia, Fernández Álvarez, Rubén, Lancharro Anchel, Aima, Ríos, Eduardo, Losada Castillo, María del Carmen, Pérez Persona, Ernesto, García Muñoz, Ricardo, Ramos, Rafael, Yáñez, Lucrecia, Bello, José Luis, Loriente, Cristina, Acha, Daniel, Villanueva, Miguel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Aged Chronic lymphocytic leukemia (CLL) Effectiveness First-line Humans Ibrutinib Leukemia, Lymphocytic, Chronic, B-Cell Piperidines Pyrazoles - adverse effects Pyrimidines - adverse effects Real-world Relapsed/refractory (R/R) Retrospective Studies Spain - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!